For research use only. Not for therapeutic Use.
SGX523 (CAT: I000156) is a highly selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase, a critical regulator of cell growth, survival, and metastasis. Its targeted mechanism of action disrupts MET signaling pathways, making it a valuable tool in oncology research. SGX523 exhibits significant antitumor activity, particularly in MET-driven cancers, including certain lung, liver, and gastric malignancies. Its high specificity and potency make it ideal for preclinical studies aimed at understanding MET’s role in tumorigenesis and developing innovative therapeutic strategies for MET-dependent cancers
| Catalog Number | I000156 |
| CAS Number | 1022150-57-7 |
| Synonyms | 6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]quinoline |
| Molecular Formula | C₁₈H₁₃N₇S |
| Purity | ≥95% |
| Target | c-Met/HGFR |
| Solubility | DMSO: ＞ 3.6 mg/mL, H2O: ＜ 1 mg/mL |
| Storage | 3 years -20C powder |
| IC50 | 4 nM |
| IUPAC Name | 6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]quinoline |
| InChI | 1S/C18H13N7S/c1-24-11-13(10-20-24)16-6-7-17-21-22-18(25(17)23-16)26-14-4-5-15-12(9-14)3-2-8-19-15/h2-11H,1H3 |
| InChIKey | BCZUAADEACICHN-UHFFFAOYSA-N |
| SMILES | CN1C=C(C=N1)C2=NN3C(=NN=C3SC4=CC5=C(C=C4)N=CC=C5)C=C2 |
